{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:20:21Z","timestamp":1776262821552,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s42000-021-00319-w","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T06:26:39Z","timestamp":1631687199000},"page":"793-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hyperparathyroidism in patients with overt and mild primary aldosteronism"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-4358","authenticated-orcid":false,"given":"Christos","family":"Gravvanis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Labrini","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spiridoula","family":"Glycofridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Voulgaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernestini","family":"Tyfoxylou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kounadi","family":"Theodora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Piaditis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0391thina","family":"Markou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"issue":"11","key":"319_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293\u20132300. https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"319_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/nejmoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS et al (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351(1):33\u201341. https:\/\/doi.org\/10.1056\/nejmoa033263","journal-title":"N Engl J Med"},{"issue":"9","key":"319_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/M17-0882","volume":"167","author":"JM Brown","year":"2017","unstructured":"Brown JM et al (2017) The spectrum of subclinical primary aldosteronism and incident hypertension. Ann Intern Med 167(9):630. https:\/\/doi.org\/10.7326\/M17-0882","journal-title":"Ann Intern Med"},{"issue":"8","key":"319_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S2213-8587(18)30174-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, Brown MJ (2018) Investigation of primary aldosteronism in patients with resistant hypertension \u2013 authors\u2019 reply. Lancet Diabetes Endocrinol 6(8):600\u2013601. https:\/\/doi.org\/10.1016\/S2213-8587(18)30174-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"319_CR5","doi-asserted-by":"publisher","first-page":"R191","DOI":"10.1530\/EJE-14-0537","volume":"172","author":"G Piaditis","year":"2015","unstructured":"Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G (2015) Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol 172(5):R191-203. https:\/\/doi.org\/10.1530\/EJE-14-0537","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"319_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown JM et al (2020) The unrecognized prevalence of primary aldosteronism. Ann Intern Med 173(1):10\u201320. https:\/\/doi.org\/10.7326\/M20-0065","journal-title":"Ann Intern Med"},{"issue":"1","key":"319_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-16-0003","volume":"175","author":"V Tsiavos","year":"2016","unstructured":"Tsiavos V et al (2016) A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism. Eur J Endocrinol 175(1):21\u201328. https:\/\/doi.org\/10.1530\/EJE-16-0003","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"319_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/cvr\/cvs092","volume":"94","author":"A Tomaschitz","year":"2012","unstructured":"Tomaschitz A et al (2012) Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res 94(1):10\u201319. https:\/\/doi.org\/10.1093\/cvr\/cvs092","journal-title":"Cardiovasc Res"},{"issue":"13","key":"319_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1055\/s-0035-1565224","volume":"47","author":"E Asbach","year":"2015","unstructured":"Asbach E, Bekeran M, Reincke M (2015) Parathyroid gland function in primary aldosteronism. Horm Metab Res 47(13):994\u2013999. https:\/\/doi.org\/10.1055\/s-0035-1565224","journal-title":"Horm Metab Res"},{"issue":"2","key":"319_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/HYPERTENSIONAHA.112.195891","volume":"60","author":"GP Rossi","year":"2012","unstructured":"Rossi GP et al (2012) Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 60(2):431\u2013436. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.195891","journal-title":"Hypertension"},{"key":"319_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/endo-129-1-489","author":"CM Isales","year":"1991","unstructured":"Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H (1991) Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. https:\/\/doi.org\/10.1210\/endo-129-1-489","journal-title":"Endocrinology"},{"issue":"2","key":"319_CR12","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1152\/ajpendo.2001.280.2.E209","volume":"280","author":"G Mazzocchi","year":"2001","unstructured":"Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG (2001) PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Metab 280(2):E209\u2013E213. https:\/\/doi.org\/10.1152\/ajpendo.2001.280.2.E209","journal-title":"Am J Physiol Metab"},{"issue":"3","key":"319_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/joe.0.1120431","volume":"112","author":"J Rosenberg","year":"1987","unstructured":"Rosenberg J, Pines M, Hurwitz S (1987) Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol 112(3):431\u2013437. https:\/\/doi.org\/10.1677\/joe.0.1120431","journal-title":"J Endocrinol"},{"issue":"4","key":"319_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00223-010-9409-5","volume":"87","author":"S Pilz","year":"2010","unstructured":"Pilz S, Tomaschitz A, M\u00e4rz W, Cavalier E, Ritz E (2010) Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int 87(4):373\u2013374. https:\/\/doi.org\/10.1007\/s00223-010-9409-5","journal-title":"Calcif Tissue Int"},{"issue":"04","key":"319_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/a-1027-6472","volume":"128","author":"E Asbach","year":"2020","unstructured":"Asbach E et al (2020) Primary and secondary hyperparathyroidism in patients with primary aldosteronism \u2013 findings from the German Conn\u2019s Registry. Exp Clin Endocrinol Diabetes 128(04):246\u2013254. https:\/\/doi.org\/10.1055\/a-1027-6472","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"319_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-123-1-199507010-00013","volume":"123","author":"G Rossi","year":"1995","unstructured":"Rossi G (1995) Diagnosis and treatment of primary aldosteronism. Ann Intern Med 123(1):73. https:\/\/doi.org\/10.7326\/0003-4819-123-1-199507010-00013","journal-title":"Ann Intern Med"},{"key":"319_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834f0451","author":"C Maniero","year":"2012","unstructured":"Maniero C et al (2012) Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. https:\/\/doi.org\/10.1097\/HJH.0b013e32834f0451","journal-title":"J Hypertens"},{"issue":"1","key":"319_CR18","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1210\/jc.2011-2183","volume":"97","author":"S Pilz","year":"2012","unstructured":"Pilz S et al (2012) Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 97(1):E75\u2013E79. https:\/\/doi.org\/10.1210\/jc.2011-2183","journal-title":"J Clin Endocrinol Metab"},{"key":"319_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/974647","volume":"2011","author":"H Schiffl","year":"2011","unstructured":"Schiffl H, Lang SM (2011) Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol 2011:1\u20136. https:\/\/doi.org\/10.1155\/2011\/974647","journal-title":"Int J Endocrinol"},{"issue":"6","key":"319_CR20","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S (2017) Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 177(6):R297\u2013R308. https:\/\/doi.org\/10.1530\/EJE-17-0485","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"319_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2013.08.016","volume":"63","author":"A Tomaschitz","year":"2014","unstructured":"Tomaschitz A et al (2014) Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 63(1):20\u201331. https:\/\/doi.org\/10.1016\/j.metabol.2013.08.016","journal-title":"Metabolism"},{"issue":"5","key":"319_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1530\/eje.0.1380543","volume":"138","author":"L Kovacs","year":"1998","unstructured":"Kovacs L, Goth M, Szabolcs I, Dohan O, Ferencz A, Szilagyi G (1998) The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 138(5):543\u2013547. https:\/\/doi.org\/10.1530\/eje.0.1380543","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"319_CR23","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","volume":"105","author":"A Vaidya","year":"2020","unstructured":"Vaidya A, Carey RM (2020) Evolution of the primary aldosteronism syndrome: updating the approach. J Clin Endocrinol Metab 105(12):3771\u20133783. https:\/\/doi.org\/10.1210\/clinem\/dgaa606","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"319_CR24","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0990","volume":"179","author":"TA Williams","year":"2018","unstructured":"Williams TA, Reincke M (2018) Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol 179(1):R19\u2013R29. https:\/\/doi.org\/10.1530\/EJE-17-0990","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"319_CR25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(5):1889\u20131916. https:\/\/doi.org\/10.1210\/jc.2015-4061","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"319_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"6","key":"319_CR27","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1210\/jc.2014-4432","volume":"100","author":"G Chen","year":"2015","unstructured":"Chen G et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100(6):2420\u20132424. https:\/\/doi.org\/10.1210\/jc.2014-4432","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"319_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.surg.2009.09.041","volume":"146","author":"L Brunaud","year":"2009","unstructured":"Brunaud L et al (2009) Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 146(6):1035\u20131041. https:\/\/doi.org\/10.1016\/j.surg.2009.09.041","journal-title":"Surgery"},{"issue":"651","key":"319_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/pgmj.56.651.45","volume":"56","author":"A Fertig","year":"1980","unstructured":"Fertig A, Webley M, Lynn JA (1980) Primary hyperparathyroidism in a patient with Conn\u2019s syndrome. Postgrad Med J 56(651):45\u201347. https:\/\/doi.org\/10.1136\/pgmj.56.651.45","journal-title":"Postgrad Med J"},{"key":"319_CR30","unstructured":"A. Concistr\u00e9 et al., \u201cPrimary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre.,\u201d Eur. Rev. Med. Pharmacol. Sci., vol. 19, no. 6, pp. 971\u20136, 2015, [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25855921"},{"issue":"7","key":"319_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/HJH.0000000000000927","volume":"34","author":"A Tomaschitz","year":"2016","unstructured":"Tomaschitz A et al (2016) Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial. J Hypertens 34(7):1347\u20131356. https:\/\/doi.org\/10.1097\/HJH.0000000000000927","journal-title":"J Hypertens"},{"key":"319_CR32","doi-asserted-by":"publisher","unstructured":"A Vaidya, JS Williams (2012) \u201cThe relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes,\u201d Metabolism: Clinical and Experimental https:\/\/doi.org\/10.1016\/j.metabol.2011.09.007","DOI":"10.1016\/j.metabol.2011.09.007"},{"key":"319_CR33","doi-asserted-by":"publisher","unstructured":"NA Ismail, NA Kamaruddin, S Azhar Shah, N Sukor (2020) \u201cThe effect of vitamin D treatment on clinical and biochemical outcomes of primary aldosteronism,\u201d Clin. Endocrinol. (Oxf), https:\/\/doi.org\/10.1111\/cen.14177","DOI":"10.1111\/cen.14177"},{"issue":"3","key":"319_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MED.0000000000000062","volume":"21","author":"JM Brown","year":"2014","unstructured":"Brown JM, Vaidya A (2014) Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes 21(3):193\u2013201. https:\/\/doi.org\/10.1097\/MED.0000000000000062","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"319_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12018-015-9182-0","volume":"13","author":"LS Bislev","year":"2015","unstructured":"Bislev LS, Sikj\u00e6r T, Rolighed L, Rejnmark L (2015) Relationship between aldosterone and parathyroid hormone, and the effect of angiotensin and aldosterone inhibition on bone health. Clin Rev Bone Miner Metab 13(3):194\u2013205. https:\/\/doi.org\/10.1007\/s12018-015-9182-0","journal-title":"Clin Rev Bone Miner Metab"},{"issue":"9","key":"319_CR36","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1210\/jc.2019-00143","volume":"104","author":"L Lenzini","year":"2019","unstructured":"Lenzini L et al (2019) PTH modulation by aldosterone and angiotensin II is blunted in hyperaldosteronism and rescued by adrenalectomy. J Clin Endocrinol Metab 104(9):3726\u20133734. https:\/\/doi.org\/10.1210\/jc.2019-00143","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"319_CR37","doi-asserted-by":"publisher","first-page":"555637","DOI":"10.19080\/JETR.2019.04.555637","volume":"4","author":"V Naik","year":"2019","unstructured":"Naik V (2019) Aldosterone and parathyroid hormone: evidence for a clinically relevant relationship. J Endocrinol Thyroid Res 4(3):555637. https:\/\/doi.org\/10.19080\/JETR.2019.04.555637","journal-title":"J Endocrinol Thyroid Res"},{"key":"319_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.159","author":"AA Zia","year":"2010","unstructured":"Zia AA et al (2010) From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res. https:\/\/doi.org\/10.1038\/hr.2010.159","journal-title":"Hypertens Res"},{"key":"319_CR39","unstructured":"Y. Zhang and B. Feng, \u201cAssociation of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis.,\u201d Int. J. Clin. Exp. Med., vol. 8, no. 9, pp. 14625\u201333, 2015, [Online]. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26628945"},{"issue":"2","key":"319_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","volume":"350","author":"NG Hattangady","year":"2012","unstructured":"Hattangady NG, Olala LO, Bollag WB, Rainey WE (2012) Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 350(2):151\u2013162. https:\/\/doi.org\/10.1016\/j.mce.2011.07.034","journal-title":"Mol Cell Endocrinol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-021-00319-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T18:48:01Z","timestamp":1637002081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-021-00319-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s42000-021-00319-w","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol is approved from the institutional ethics committee of the General Hospital of Athens G Gennimatas, Greece, and the reporting of the study conforms to the Guidelines for Good Clinical Practice, the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}